Tests elecoglipron alone or with dapagliflozin for type 2 diabetes
Tests elecoglipron, alone or with dapagliflozin, in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Anderson, Birmingham, Bowie, Bridgeport, Conyers, Covington, Daphne, Decatur, El Dorado, Englewood, Fort Worth, Hinesville, Irving, Jacksonville, Kansas City, Knoxville, Las Vegas, Lexington, Lomita, Los Alamitos, Newton, Orlando, Renton, San Diego, Southfield, St Louis, and Walnut Creek, United StatesSee the 27 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled with lifestyle changes alone or with their current diabetes medicine.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes for at least 90 days before screening, with HbA1c of ≥ 7% (53 mmol/mol) to ≤ 10.5% (53 to 91.3 mmol/mol). Poorly managed with lifestyle alone or on stable background glucose-lowering medicine.
- Earlier treatment
- People on background glucose-lowering medicine must be on a stable treatment.
- Biomarker or test result
- HbA1c of ≥ 7% (53 mmol/mol) to ≤ 10.5% (53 to 91.3 mmol/mol). BMI of ≥ 23 kg/m2 at screening.
Main reasons for not taking part
- Type 1 diabetes, other secondary forms of diabetes, or a history of ketoacidosis or hyperosmolar coma
- More than one severe low blood sugar episode in the 180 days before screening, or not noticing low blood sugar symptoms
- History of acute or chronic pancreatitis
- Severe congestive heart failure (New York Heart Association IV)
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Read by machine on 9 November 2026.
Where in United States
- AndersonAnderson, United StatesNot yet recruiting
- BirminghamBirmingham, United StatesNot yet recruiting
- BowieBowie, United StatesNot yet recruiting
- BridgeportBridgeport, United StatesNot yet recruiting
- ConyersConyers, United StatesNot yet recruiting
- CovingtonCovington, United StatesNot yet recruiting
- DaphneDaphne, United StatesNot yet recruiting
- DecaturDecatur, United StatesNot yet recruiting
- El DoradoEl Dorado, United StatesNot yet recruiting
- EnglewoodEnglewood, United StatesNot yet recruiting
- Fort WorthFort Worth, United StatesNo longer taking part
- HinesvilleHinesville, United StatesNot yet recruiting
- IrvingIrving, United StatesNot yet recruiting
- JacksonvilleJacksonville, United StatesNot yet recruiting
- Kansas CityKansas City, United StatesNot yet recruiting
- KnoxvilleKnoxville, United StatesNot yet recruiting
- Las VegasLas Vegas, United StatesNot yet recruiting
- LexingtonLexington, United StatesNot yet recruiting
- LomitaLomita, United StatesNot yet recruiting
- Los AlamitosLos Alamitos, United StatesNot yet recruiting
- NewtonNewton, United StatesNot yet recruiting
- OrlandoOrlando, United StatesNot yet recruiting
- RentonRenton, United StatesNot yet recruiting
- San DiegoSan Diego, United StatesNo longer taking part
- SouthfieldSouthfield, United StatesNot yet recruiting
- St LouisSt Louis, United StatesNot yet recruiting
- Walnut CreekWalnut Creek, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662044EU 2025-523936-37-00
- Record updated
- 31 August 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication; HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.